| |
| |
|
| Insider
Information: |
Harper Sean E |
| Relationship: |
10% Owner |
| City: |
Thousand Oaks |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
9,846,811 |
|
|
Indirect Shares
|
735,984 |
|
|
| Direct
Value |
$64,300,457 |
|
|
|
Indirect Value
|
$11,680,066 |
|
|
| Total
Shares |
10,582,795 |
|
|
| Total
Value |
$75,980,523 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -71.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amgen Inc |
AMGN |
EVP, Research & Develo... |
2018-07-16 |
56,082 |
|
0 |
Premium* |
|
|
Acelyrin, Inc. |
SLRN |
10% Owner |
2023-05-09 |
9,790,729 |
2023-05-09 |
0 |
Premium* |
|
|
Kyverna Therapeutics |
KYTX |
10% Owner |
2024-02-12 |
0 |
2024-02-12 |
735,984 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
64 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLRN |
Acelyrin, Inc. |
10% Owner |
– – • |
2023-05-09 |
4 |
B |
$18.00 |
$22,500,000 |
D/D |
1,250,000 |
9,790,729 |
2.45 |
% |
|
| SLRN |
Acelyrin, Inc. |
10% Owner |
– – • |
2023-05-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,540,729 |
8,540,729 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & DevelopmentOff |
• – – |
2012-02-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
42,150 |
|
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,140 |
46,290 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-03-16 |
4 |
D |
$68.26 |
$103,687 |
D/D |
(1,519) |
44,771 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,654 |
52,911 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-04-28 |
4 |
D |
$71.64 |
$37,683 |
D/D |
(526) |
52,385 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-04-29 |
4 |
D |
$71.64 |
$182,324 |
D/D |
(2,545) |
49,840 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-05-03 |
4 |
D |
$71.17 |
$815,110 |
D/D |
(11,453) |
52,387 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• – – |
2012-05-03 |
4 |
OE |
$42.13 |
$656,300 |
D/D |
14,000 |
63,840 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2012-07-27 |
4 |
OE |
$58.43 |
$2,730,172 |
D/D |
39,900 |
84,332 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2012-07-27 |
4 |
S |
$82.33 |
$3,285,087 |
D/D |
(39,900) |
52,432 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
7,477 |
59,981 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
13,257 |
73,238 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-03-15 |
4 |
D |
$92.18 |
$637,701 |
D/D |
(6,918) |
66,403 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-04-25 |
4 |
D |
$104.93 |
$108,498 |
D/D |
(1,034) |
65,369 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-04-26 |
4 |
D |
$108.66 |
$65,305 |
D/D |
(601) |
64,768 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-04-28 |
4 |
D |
$108.38 |
$63,727 |
D/D |
(588) |
64,180 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-05-02 |
4 |
S |
$106.32 |
$850,590 |
D/D |
(8,000) |
64,180 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2013-05-02 |
4 |
OE |
$50.44 |
$403,520 |
D/D |
8,000 |
72,180 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,044 |
69,439 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,724 |
84,163 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-03-14 |
4 |
D |
$123.96 |
$952,385 |
D/D |
(7,683) |
76,588 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-04-25 |
4 |
D |
$113.72 |
$117,586 |
D/D |
(1,034) |
75,554 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Research & Development |
• • – |
2014-04-26 |
4 |
D |
$111.41 |
$66,957 |
D/D |
(601) |
74,953 |
0 |
- |
|
64 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
